Sangeeta Sehgal, MD
Internal Medicine · Valparaiso, INNPI 1992766224
Payments from drug & device makers
Across 121 payments — averaging $27.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$743
- AbbVie$327
- Medtronic$309
- Abiomed$284
- Edwards Lifesciences$238
- Boston Scientific$167
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,362100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 42 | $743 |
| AbbVie(2 entities) | 17 | $327 |
| Medtronic(2 entities) | 4 | $309 |
| Abiomed | 2 | $284 |
| Edwards Lifesciences | 3 | $238 |
| Boston Scientific | 2 | $167 |
| Johnson & Johnson | 5 | $150 |
| Lilly USA, LLC | 2 | $137 |
| Boehringer Ingelheim | 2 | $129 |
| Novartis | 1 | $125 |
| Inari Medical, Inc. | 1 | $122 |
| GSK | 8 | $120 |
| Pfizer | 5 | $93 |
| Novo Nordisk | 6 | $91 |
| AstraZeneca | 4 | $63 |
| Merck | 3 | $52 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Bayer | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$284
- KRYSTEXXA$250
- FLOWTRIEVER CATHETER, S$244
- JARDIANCE$235
- Edwards SAPIEN 3 Transcatheter Heart Valve$131
- WATCHMAN Access System$125
- LEQVIO$125
- Azure$100
How this compares
$3,373 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $92,651 |
| JanuviaSitagliptin Phosphate | 78 | $85,370 |
| MounjaroTirzepatide | 56 | $53,972 |
| Repatha SureclickEvolocumab | 52 | $51,326 |
| FarxigaDapagliflozin Propanediol | 26 | $26,230 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $15,513 |
| EliquisApixaban | 16 | $14,827 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $12,476 |
| SynthroidLevothyroxine Sodium | 119 | $10,850 |
| JardianceEmpagliflozin | 12 | $10,726 |
| MyrbetriqMirabegron | 18 | $8,001 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $6,923 |
| Praluent PenAlirocumab | 13 | $6,234 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,826 |
| Levothyroxine Sodium | 561 | $5,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $91 | $92,65162 claims |
| MerckJanuvia | $52 | $85,37078 claims |
| Lilly USA, LLCMounjaro | $137 | $53,97256 claims |
| AstraZenecaFarxiga, Symbicort | $63 | $32,05639 claims |
| PfizerEliquis | $93 | $14,82716 claims |
| GSKTrelegy Ellipta | $120 | $12,47617 claims |
| AbbVieSynthroid | $327 | $10,850119 claims |
| Boehringer IngelheimJardiance | $129 | $10,72612 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $8,00118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Valparaiso
- Robert BuynakValparaiso$24.2M
- Crystal TuncayValparaiso$33K
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.